Sidoti Forecasts Reduced Earnings for USANA Health Sciences

USANA Health Sciences, Inc. (NYSE:USNA) – Analysts at Sidoti cut their Q3 2026 earnings estimates for shares of USANA Health Sciences in a research report issued on Wednesday, August 5th. Sidoti analyst A. Lebiedzinski now anticipates that the company will post earnings per share of $0.09 for the quarter, down from their prior estimate of $0.43. The consensus estimate for USANA Health Sciences’ current full-year earnings is $0.76 per share. Sidoti also issued estimates for USANA Health Sciences’ Q4 2026 earnings at $0.11 EPS, FY2026 earnings at $0.76 EPS, Q1 2027 earnings at $0.31 EPS, Q2 2027 earnings at $0.43 EPS, Q3 2027 earnings at $0.47 EPS, Q4 2027 earnings at $0.50 EPS and FY2027 earnings at $1.77 EPS.

USANA Health Sciences (NYSE:USNA) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($0.07) earnings per share for the quarter, missing analysts’ consensus estimates of $0.43 by ($0.50). The company had revenue of $223.27 million for the quarter, compared to analyst estimates of $235.00 million. USANA Health Sciences had a positive return on equity of 3.41% and a negative net margin of 2.43%.USANA Health Sciences has set its FY 2026 guidance at 0.760-0.760 EPS.

Other equities research analysts have also recently issued reports about the company. Zacks Research cut USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 22nd. Weiss Ratings reaffirmed a “sell (d)” rating on shares of USANA Health Sciences in a research note on Wednesday, June 24th. Finally, Wall Street Zen upgraded USANA Health Sciences from a “hold” rating to a “buy” rating in a research report on Saturday, June 20th. One investment analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, USANA Health Sciences has a consensus rating of “Reduce”.

USANA Health Sciences Stock Down 0.8%

USNA stock opened at $14.87 on Friday. The stock has a market capitalization of $274.44 million, a P/E ratio of -12.29, a P/E/G ratio of 1.64 and a beta of 0.73. The firm has a 50-day simple moving average of $20.47 and a 200-day simple moving average of $19.69. USANA Health Sciences has a 52 week low of $14.35 and a 52 week high of $32.32.

Insider Buying and Selling at USANA Health Sciences

In other USANA Health Sciences news, Director John Turman Fleming sold 2,450 shares of the firm’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $17.93, for a total value of $43,928.50. Following the completion of the sale, the director directly owned 4,230 shares of the company’s stock, valued at $75,843.90. This trade represents a 36.68% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO G Doug Iiekking sold 5,360 shares of USANA Health Sciences stock in a transaction on Wednesday, May 27th. The stock was sold at an average price of $18.75, for a total value of $100,500.00. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 13,869 shares of company stock worth $261,441 in the last three months. 0.82% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On USANA Health Sciences

A number of institutional investors have recently bought and sold shares of the company. State of Alaska Department of Revenue increased its stake in USANA Health Sciences by 8.5% in the fourth quarter. State of Alaska Department of Revenue now owns 6,666 shares of the company’s stock valued at $130,000 after purchasing an additional 525 shares during the last quarter. Russell Investments Group Ltd. lifted its position in shares of USANA Health Sciences by 4.6% during the 4th quarter. Russell Investments Group Ltd. now owns 12,431 shares of the company’s stock worth $244,000 after buying an additional 542 shares during the last quarter. Quantbot Technologies LP boosted its holdings in shares of USANA Health Sciences by 19.5% in the 2nd quarter. Quantbot Technologies LP now owns 3,957 shares of the company’s stock valued at $121,000 after buying an additional 646 shares in the last quarter. Intech Investment Management LLC boosted its holdings in shares of USANA Health Sciences by 13.5% in the 3rd quarter. Intech Investment Management LLC now owns 7,722 shares of the company’s stock valued at $213,000 after buying an additional 918 shares in the last quarter. Finally, National Bank of Canada FI grew its position in shares of USANA Health Sciences by 166.6% in the 3rd quarter. National Bank of Canada FI now owns 1,922 shares of the company’s stock valued at $53,000 after buying an additional 1,201 shares during the last quarter. 54.25% of the stock is owned by hedge funds and other institutional investors.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc is a Utah?based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company’s portfolio includes vitamins, minerals, dietary supplements, weight?management products and skin?care formulations. USANA’s products are formulated in its own laboratories to meet pharmaceutical?grade standards, and the company has invested heavily in research and development and quality control to support its offerings.

Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.